Loading…
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population
Background & Aims Time-dependent statistics have been used to assess liver fibrosis progression (LFP) in liver diseases from birth to first biopsy, in a limited number of patients. Non-invasive biomarkers such as FibroTest (FT) should allow the estimation of LFP on larger populations. We aimed a...
Saved in:
Published in: | Journal of hepatology 2012-09, Vol.57 (3), p.541-548 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c441t-f61e8b1dbb58f78f0409338c4454beef5e49f6eeec4e149e440d6275f5756633 |
---|---|
cites | cdi_FETCH-LOGICAL-c441t-f61e8b1dbb58f78f0409338c4454beef5e49f6eeec4e149e440d6275f5756633 |
container_end_page | 548 |
container_issue | 3 |
container_start_page | 541 |
container_title | Journal of hepatology |
container_volume | 57 |
creator | Poynard, Thierry Munteanu, Mona Deckmyn, Olivier Ngo, Yen Drane, Fabienne Castille, Jean Marie Housset, Chantal Ratziu, Vlad Imbert-Bismut, Françoise |
description | Background & Aims Time-dependent statistics have been used to assess liver fibrosis progression (LFP) in liver diseases from birth to first biopsy, in a limited number of patients. Non-invasive biomarkers such as FibroTest (FT) should allow the estimation of LFP on larger populations. We aimed at validating this concept by comparing LFP using FT vs. biopsy (P1) and then at applying the non-invasive method to a large population (P2). Methods In P1, LFP was assessed using biopsy and FT in 2472 untreated patients: 770 with chronic hepatitis C, 723 with hepatitis B, 761 with non-alcoholic fatty liver disease (NAFLD), and 218 with alcoholic fatty liver disease (ALD). In P2, 342,346 interpretable FT prospectively measured were used. LFP was estimated using transition rates (cumulative hazard rate) to cirrhosis (F4) or to minimal fibrosis (>F0). Results In P1, there was a significant concordance between FT and biopsy estimates of hazards with intraclass correlation (ICC) = 0.961 (95% CI 0.948–0.970) and 0.899 (95% CI 0.135–0.969) for F4 and >F0, respectively. This concordance persisted according to the disease and the gender. The more rapid LFP to F4 (biopsy/FT) was observed for men with ALD (1.44/1.62), and the slower for women with NAFLD (0.09/0.02). In P2, the LFP started to increase for men at the age of 30 years. The cumulative fibrosis progression rate to minimal fibrosis in women crossed the “man curve” around the age of 80 years. The following factors were associated with LFP to F4 (all p |
doi_str_mv | 10.1016/j.jhep.2012.04.025 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1034516594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827812003479</els_id><sourcerecordid>1034516594</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-f61e8b1dbb58f78f0409338c4454beef5e49f6eeec4e149e440d6275f5756633</originalsourceid><addsrcrecordid>eNp9klFrFDEQx4Mo9lr9Aj5IXoT24c4km-R2RQQpVoWCgoevIZudnLnmNttkt9CP4rd11jsV-iAEEia__2Qy_yHkBWcrzrh-vVvtfsCwEoyLFZMrJtQjsuCasSXTkj8mC4TqZS3W9Qk5LWXHGKtYI5-SEyE0F01TL8jP7zaGzo4h9TR5GsMdZOpDm1MJhbYh7W2-wdD51RzbQBkvqE-Z2lKglNBvH0qGnLZ5vkr9G_o1J0yKy6XewTBS23eI5oKnYYjBHR4OPbU02rwFOqRhir-jz8gTb2OB58f9jGyuPmwuPy2vv3z8fPn-eumk5OPSaw51y7u2VbVf155J1lRVjZdKtgBegWy8BgAngcsGpGSdFmvl1VppXVVn5PyQFgu_nfB_Zh-KgxhtD2kqhrNKKq5VIxEVB9ThV0sGb4YcsD_3CJnZEbMzsyNmdsQwadARFL085p_aPXR_JX8sQODVEbDF2eiz7V0o_zgtlGrUnOjtgQNsxl2AbIoLgG3tQgY3mi6F_9fx7oHcxdCjA_EG7qHs0pR7bLPhpqDGfJtnZx4dLnBq5LqpfgFhFMFr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1034516594</pqid></control><display><type>article</type><title>Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Poynard, Thierry ; Munteanu, Mona ; Deckmyn, Olivier ; Ngo, Yen ; Drane, Fabienne ; Castille, Jean Marie ; Housset, Chantal ; Ratziu, Vlad ; Imbert-Bismut, Françoise</creator><creatorcontrib>Poynard, Thierry ; Munteanu, Mona ; Deckmyn, Olivier ; Ngo, Yen ; Drane, Fabienne ; Castille, Jean Marie ; Housset, Chantal ; Ratziu, Vlad ; Imbert-Bismut, Françoise</creatorcontrib><description>Background & Aims Time-dependent statistics have been used to assess liver fibrosis progression (LFP) in liver diseases from birth to first biopsy, in a limited number of patients. Non-invasive biomarkers such as FibroTest (FT) should allow the estimation of LFP on larger populations. We aimed at validating this concept by comparing LFP using FT vs. biopsy (P1) and then at applying the non-invasive method to a large population (P2). Methods In P1, LFP was assessed using biopsy and FT in 2472 untreated patients: 770 with chronic hepatitis C, 723 with hepatitis B, 761 with non-alcoholic fatty liver disease (NAFLD), and 218 with alcoholic fatty liver disease (ALD). In P2, 342,346 interpretable FT prospectively measured were used. LFP was estimated using transition rates (cumulative hazard rate) to cirrhosis (F4) or to minimal fibrosis (>F0). Results In P1, there was a significant concordance between FT and biopsy estimates of hazards with intraclass correlation (ICC) = 0.961 (95% CI 0.948–0.970) and 0.899 (95% CI 0.135–0.969) for F4 and >F0, respectively. This concordance persisted according to the disease and the gender. The more rapid LFP to F4 (biopsy/FT) was observed for men with ALD (1.44/1.62), and the slower for women with NAFLD (0.09/0.02). In P2, the LFP started to increase for men at the age of 30 years. The cumulative fibrosis progression rate to minimal fibrosis in women crossed the “man curve” around the age of 80 years. The following factors were associated with LFP to F4 (all p <0.0001): male gender (Relative Risk = 3.29), HIV co-infection (2.33), and residency in Middle East (2.67) or Eastern Europe (2.15). Conclusions Validated biomarkers such as FibroTest should allow powerful analysis of fibrosis progression in chronic liver diseases and better identification of risk factors.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2012.04.025</identifier><identifier>PMID: 22612998</identifier><identifier>CODEN: JOHEEC</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Adult ; Age Factors ; alpha-Macroglobulins - metabolism ; Apolipoprotein A-I - blood ; Bilirubin - blood ; Biological and medical sciences ; Biomarkers - blood ; Biopsy ; Disease Progression ; Europe, Eastern - ethnology ; Fatty Liver, Alcoholic - complications ; Female ; Fibrosis progression rates ; FibroSure ; FibroTest ; gamma-Glutamyltransferase - blood ; Gastroenterology and Hepatology ; Gastroenterology. Liver. Pancreas. Abdomen ; Haptoglobins - metabolism ; Hepatitis B, Chronic - complications ; Hepatitis C, Chronic - complications ; HIV coinfection ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Liver Cirrhosis - blood ; Liver Cirrhosis - etiology ; Liver Cirrhosis - pathology ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Middle East - ethnology ; Normal transaminases ; Other diseases. Semiology ; Risk factors of fibrosis ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>Journal of hepatology, 2012-09, Vol.57 (3), p.541-548</ispartof><rights>European Association for the Study of the Liver</rights><rights>2012 European Association for the Study of the Liver</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-f61e8b1dbb58f78f0409338c4454beef5e49f6eeec4e149e440d6275f5756633</citedby><cites>FETCH-LOGICAL-c441t-f61e8b1dbb58f78f0409338c4454beef5e49f6eeec4e149e440d6275f5756633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26255955$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22612998$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poynard, Thierry</creatorcontrib><creatorcontrib>Munteanu, Mona</creatorcontrib><creatorcontrib>Deckmyn, Olivier</creatorcontrib><creatorcontrib>Ngo, Yen</creatorcontrib><creatorcontrib>Drane, Fabienne</creatorcontrib><creatorcontrib>Castille, Jean Marie</creatorcontrib><creatorcontrib>Housset, Chantal</creatorcontrib><creatorcontrib>Ratziu, Vlad</creatorcontrib><creatorcontrib>Imbert-Bismut, Françoise</creatorcontrib><title>Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Background & Aims Time-dependent statistics have been used to assess liver fibrosis progression (LFP) in liver diseases from birth to first biopsy, in a limited number of patients. Non-invasive biomarkers such as FibroTest (FT) should allow the estimation of LFP on larger populations. We aimed at validating this concept by comparing LFP using FT vs. biopsy (P1) and then at applying the non-invasive method to a large population (P2). Methods In P1, LFP was assessed using biopsy and FT in 2472 untreated patients: 770 with chronic hepatitis C, 723 with hepatitis B, 761 with non-alcoholic fatty liver disease (NAFLD), and 218 with alcoholic fatty liver disease (ALD). In P2, 342,346 interpretable FT prospectively measured were used. LFP was estimated using transition rates (cumulative hazard rate) to cirrhosis (F4) or to minimal fibrosis (>F0). Results In P1, there was a significant concordance between FT and biopsy estimates of hazards with intraclass correlation (ICC) = 0.961 (95% CI 0.948–0.970) and 0.899 (95% CI 0.135–0.969) for F4 and >F0, respectively. This concordance persisted according to the disease and the gender. The more rapid LFP to F4 (biopsy/FT) was observed for men with ALD (1.44/1.62), and the slower for women with NAFLD (0.09/0.02). In P2, the LFP started to increase for men at the age of 30 years. The cumulative fibrosis progression rate to minimal fibrosis in women crossed the “man curve” around the age of 80 years. The following factors were associated with LFP to F4 (all p <0.0001): male gender (Relative Risk = 3.29), HIV co-infection (2.33), and residency in Middle East (2.67) or Eastern Europe (2.15). Conclusions Validated biomarkers such as FibroTest should allow powerful analysis of fibrosis progression in chronic liver diseases and better identification of risk factors.</description><subject>Adult</subject><subject>Age Factors</subject><subject>alpha-Macroglobulins - metabolism</subject><subject>Apolipoprotein A-I - blood</subject><subject>Bilirubin - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Biopsy</subject><subject>Disease Progression</subject><subject>Europe, Eastern - ethnology</subject><subject>Fatty Liver, Alcoholic - complications</subject><subject>Female</subject><subject>Fibrosis progression rates</subject><subject>FibroSure</subject><subject>FibroTest</subject><subject>gamma-Glutamyltransferase - blood</subject><subject>Gastroenterology and Hepatology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Haptoglobins - metabolism</subject><subject>Hepatitis B, Chronic - complications</subject><subject>Hepatitis C, Chronic - complications</subject><subject>HIV coinfection</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Liver Cirrhosis - blood</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Middle East - ethnology</subject><subject>Normal transaminases</subject><subject>Other diseases. Semiology</subject><subject>Risk factors of fibrosis</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9klFrFDEQx4Mo9lr9Aj5IXoT24c4km-R2RQQpVoWCgoevIZudnLnmNttkt9CP4rd11jsV-iAEEia__2Qy_yHkBWcrzrh-vVvtfsCwEoyLFZMrJtQjsuCasSXTkj8mC4TqZS3W9Qk5LWXHGKtYI5-SEyE0F01TL8jP7zaGzo4h9TR5GsMdZOpDm1MJhbYh7W2-wdD51RzbQBkvqE-Z2lKglNBvH0qGnLZ5vkr9G_o1J0yKy6XewTBS23eI5oKnYYjBHR4OPbU02rwFOqRhir-jz8gTb2OB58f9jGyuPmwuPy2vv3z8fPn-eumk5OPSaw51y7u2VbVf155J1lRVjZdKtgBegWy8BgAngcsGpGSdFmvl1VppXVVn5PyQFgu_nfB_Zh-KgxhtD2kqhrNKKq5VIxEVB9ThV0sGb4YcsD_3CJnZEbMzsyNmdsQwadARFL085p_aPXR_JX8sQODVEbDF2eiz7V0o_zgtlGrUnOjtgQNsxl2AbIoLgG3tQgY3mi6F_9fx7oHcxdCjA_EG7qHs0pR7bLPhpqDGfJtnZx4dLnBq5LqpfgFhFMFr</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Poynard, Thierry</creator><creator>Munteanu, Mona</creator><creator>Deckmyn, Olivier</creator><creator>Ngo, Yen</creator><creator>Drane, Fabienne</creator><creator>Castille, Jean Marie</creator><creator>Housset, Chantal</creator><creator>Ratziu, Vlad</creator><creator>Imbert-Bismut, Françoise</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120901</creationdate><title>Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population</title><author>Poynard, Thierry ; Munteanu, Mona ; Deckmyn, Olivier ; Ngo, Yen ; Drane, Fabienne ; Castille, Jean Marie ; Housset, Chantal ; Ratziu, Vlad ; Imbert-Bismut, Françoise</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-f61e8b1dbb58f78f0409338c4454beef5e49f6eeec4e149e440d6275f5756633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>alpha-Macroglobulins - metabolism</topic><topic>Apolipoprotein A-I - blood</topic><topic>Bilirubin - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Biopsy</topic><topic>Disease Progression</topic><topic>Europe, Eastern - ethnology</topic><topic>Fatty Liver, Alcoholic - complications</topic><topic>Female</topic><topic>Fibrosis progression rates</topic><topic>FibroSure</topic><topic>FibroTest</topic><topic>gamma-Glutamyltransferase - blood</topic><topic>Gastroenterology and Hepatology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Haptoglobins - metabolism</topic><topic>Hepatitis B, Chronic - complications</topic><topic>Hepatitis C, Chronic - complications</topic><topic>HIV coinfection</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Liver Cirrhosis - blood</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Middle East - ethnology</topic><topic>Normal transaminases</topic><topic>Other diseases. Semiology</topic><topic>Risk factors of fibrosis</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poynard, Thierry</creatorcontrib><creatorcontrib>Munteanu, Mona</creatorcontrib><creatorcontrib>Deckmyn, Olivier</creatorcontrib><creatorcontrib>Ngo, Yen</creatorcontrib><creatorcontrib>Drane, Fabienne</creatorcontrib><creatorcontrib>Castille, Jean Marie</creatorcontrib><creatorcontrib>Housset, Chantal</creatorcontrib><creatorcontrib>Ratziu, Vlad</creatorcontrib><creatorcontrib>Imbert-Bismut, Françoise</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poynard, Thierry</au><au>Munteanu, Mona</au><au>Deckmyn, Olivier</au><au>Ngo, Yen</au><au>Drane, Fabienne</au><au>Castille, Jean Marie</au><au>Housset, Chantal</au><au>Ratziu, Vlad</au><au>Imbert-Bismut, Françoise</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>57</volume><issue>3</issue><spage>541</spage><epage>548</epage><pages>541-548</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><coden>JOHEEC</coden><abstract>Background & Aims Time-dependent statistics have been used to assess liver fibrosis progression (LFP) in liver diseases from birth to first biopsy, in a limited number of patients. Non-invasive biomarkers such as FibroTest (FT) should allow the estimation of LFP on larger populations. We aimed at validating this concept by comparing LFP using FT vs. biopsy (P1) and then at applying the non-invasive method to a large population (P2). Methods In P1, LFP was assessed using biopsy and FT in 2472 untreated patients: 770 with chronic hepatitis C, 723 with hepatitis B, 761 with non-alcoholic fatty liver disease (NAFLD), and 218 with alcoholic fatty liver disease (ALD). In P2, 342,346 interpretable FT prospectively measured were used. LFP was estimated using transition rates (cumulative hazard rate) to cirrhosis (F4) or to minimal fibrosis (>F0). Results In P1, there was a significant concordance between FT and biopsy estimates of hazards with intraclass correlation (ICC) = 0.961 (95% CI 0.948–0.970) and 0.899 (95% CI 0.135–0.969) for F4 and >F0, respectively. This concordance persisted according to the disease and the gender. The more rapid LFP to F4 (biopsy/FT) was observed for men with ALD (1.44/1.62), and the slower for women with NAFLD (0.09/0.02). In P2, the LFP started to increase for men at the age of 30 years. The cumulative fibrosis progression rate to minimal fibrosis in women crossed the “man curve” around the age of 80 years. The following factors were associated with LFP to F4 (all p <0.0001): male gender (Relative Risk = 3.29), HIV co-infection (2.33), and residency in Middle East (2.67) or Eastern Europe (2.15). Conclusions Validated biomarkers such as FibroTest should allow powerful analysis of fibrosis progression in chronic liver diseases and better identification of risk factors.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>22612998</pmid><doi>10.1016/j.jhep.2012.04.025</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0168-8278 |
ispartof | Journal of hepatology, 2012-09, Vol.57 (3), p.541-548 |
issn | 0168-8278 1600-0641 |
language | eng |
recordid | cdi_proquest_miscellaneous_1034516594 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Adult Age Factors alpha-Macroglobulins - metabolism Apolipoprotein A-I - blood Bilirubin - blood Biological and medical sciences Biomarkers - blood Biopsy Disease Progression Europe, Eastern - ethnology Fatty Liver, Alcoholic - complications Female Fibrosis progression rates FibroSure FibroTest gamma-Glutamyltransferase - blood Gastroenterology and Hepatology Gastroenterology. Liver. Pancreas. Abdomen Haptoglobins - metabolism Hepatitis B, Chronic - complications Hepatitis C, Chronic - complications HIV coinfection Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Liver Cirrhosis - blood Liver Cirrhosis - etiology Liver Cirrhosis - pathology Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Middle East - ethnology Normal transaminases Other diseases. Semiology Risk factors of fibrosis Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
title | Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T09%3A48%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validation%20of%20liver%20fibrosis%20biomarker%20(FibroTest)%20for%20assessing%20liver%20fibrosis%20progression:%20Proof%20of%20concept%20and%20first%20application%20in%20a%20large%20population&rft.jtitle=Journal%20of%20hepatology&rft.au=Poynard,%20Thierry&rft.date=2012-09-01&rft.volume=57&rft.issue=3&rft.spage=541&rft.epage=548&rft.pages=541-548&rft.issn=0168-8278&rft.eissn=1600-0641&rft.coden=JOHEEC&rft_id=info:doi/10.1016/j.jhep.2012.04.025&rft_dat=%3Cproquest_cross%3E1034516594%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c441t-f61e8b1dbb58f78f0409338c4454beef5e49f6eeec4e149e440d6275f5756633%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1034516594&rft_id=info:pmid/22612998&rfr_iscdi=true |